| (Values in U.S. Thousands) | Mar, 2019 | Dec, 2018 | Sep, 2018 | Jun, 2018 | Mar, 2018 |
| Sales | 7,360 | 4,910 | 21,560 | 4,910 | 4,040 |
| Sales Growth | +49.90% | -77.23% | +339.10% | +21.53% | -61.38% |
| Net Income | -6,790 | -8,630 | 8,830 | -6,370 | -8,550 |
| Net Income Growth | +21.32% | -197.74% | +238.62% | +25.50% | +45.19% |
Aratana Theraptcs (PETX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas.
Fiscal Year End Date: 12/31